Next Article in Journal
Predicting “Heart Age” Using Electrocardiography
Previous Article in Journal
Acknowledgement to Reviewers of the Journal of Personalized Medicine in 2013
Previous Article in Special Issue
The Need for Clinical Decision Support Integrated with the Electronic Health Record for the Clinical Application of Whole Genome Sequencing Information
J. Pers. Med. 2014, 4(1), 52-64; doi:10.3390/jpm4010052
Commentary

The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2)

1,* , 2
, 3
, 4
, 5
, 5
 and 6
1 Department of Surgery, Rutgers Cancer Center Institute of New Jersey, 195 Little Albany Street, Room 2007, New Brunswick, NJ 08901, USA 2 Department of Medicine, University of Southern California, 1441 Eastlake Avenue, Suite 3455, Los Angeles, CA 90033, USA 3 Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093, USA 4 Beth Israel Hospital Deaconess Medical Center, Masco Building, 375 Longwood Avenue, Boston, MA 02215, USA 5 Prometheus Laboratories Inc., 9410 Carroll Park Drive, San Diego, CA 92121, USA 6 Duke University Medical Center, 10 Bryan Searle Drive, Mudd Building, Rm 437, Durham, NC 27710, USA
* Author to whom correspondence should be addressed.
Received: 27 November 2013 / Revised: 15 February 2014 / Accepted: 27 February 2014 / Published: 7 March 2014
(This article belongs to the Special Issue Feature Paper 2013)
View Full-Text   |   Download PDF [719 KB, uploaded 7 March 2014]   |   Browse Figures

Abstract

Registries evaluating un-randomized patients have provided valuable information with respect to a therapy’s utility, treatment practices, and evolution over time. While immunotherapy for cancer has been around for more than three decades, data collection in the form of a registry has not been undertaken. The authors believe that establishing a registry to study HD IL-2 immunotherapy, which has been the only systemic therapy producing long term unmaintained remissions for advanced kidney cancer and melanoma for over 20 years, will be an important resource in understanding the impact of immunotherapy with HD IL-2 in a rapidly changing therapeutic environment. Optimizing administration and improving selection of appropriate patients likely to benefit from HD IL-2 immunotherapy are two of many benefits to be derived from this endeavor.
Keywords: oncology; cancer; registry; immunotherapy; interleukin-2; melanoma; renal cell carcinoma oncology; cancer; registry; immunotherapy; interleukin-2; melanoma; renal cell carcinoma
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Export to BibTeX |
EndNote


MDPI and ACS Style

Kaufman, H.L.; Wong, M.K.; Daniels, G.A.; McDermott, D.F.; Aung, S.; Lowder, J.N.; Morse, M.A. The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2). J. Pers. Med. 2014, 4, 52-64.

View more citation formats

Related Articles

Article Metrics

Comments

Citing Articles

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert